Article (Published version) (209 Kb) - 
Free access
Highlights
More informations
Scientific Article
unige:93800 
 |
Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect |
|
| Authors | ||
| Published in | Frontiers in Pharmacology. 2016, vol. 7, p. 494 | |
| Abstract | We report a patient who presented a non-ST segment elevation myocardial infarction in the context of severe normocytic hypochromic anemia related to gastrointestinal bleeding, 3 months after switching anticoagulant from the vitamin K antagonist acenocoumarol to the direct oral anticoagulant rivaroxaban. High levels of both anti-Xa activity and rivaroxaban plasma concentrations were measured despite rivaroxaban withdrawal, suggesting reduced elimination/drug clearance. Estimated half-life was 2-3 times longer than usually reported. The patient is a homozygous carrier of ABCB1 variant alleles, which could have participated to reduced elimination of rivaroxaban. Furthermore, CYP3A4/5 phenotyping showed moderately reduced enzyme activity. Drug-drug interaction with simvastatin may have contributed to decreased rivaroxaban elimination. Although in the present case moderate acute renal failure probably played a role, more clinical data are required to elucidate the impact of ABCB1 polymorphism on rivaroxaban pharmacokinetics and bleeding complications. | |
| Identifiers | PMID: 28066243 | |
| Full text | ||
| Structures | ||
| Research groups | Geneva Platelet Group (13) Groupe Desmeules Jules (pharmacologie/toxicologie) (567) | |
| Citation (ISO format) | ING LORENZINI, Kuntheavy et al. Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect. In: Frontiers in Pharmacology, 2016, vol. 7, p. 494. https://archive-ouverte.unige.ch/unige:93800 |
84 hits 
27 downloads 
Contact an author
Update